Phase 1 dose-escalation RCT in 60 healthy participants: single subcutaneous or intravenous doses of VEL-101 (anti-CD28) vs placebo were generally well tolerated, mostly mild-moderate adverse events; one serious event (grade 3 rhabdomyolysis) resolved.
RCTn = 60
Tremblay et al. Safety, Pharmacokinetics, and Pharmacodynamics of Fixed-dose, Subcutaneous, and Intravenous Administration of VEL-101, an Anti-CD28 PEGylated Monoclonal Antibody Fragment, in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase 1 Study